Clinical Trials Logo

B-cell Non-Hodgkin's Lymphoma clinical trials

View clinical trials related to B-cell Non-Hodgkin's Lymphoma.

Filter by:

NCT ID: NCT06314828 Not yet recruiting - Clinical trials for B-cell Non-Hodgkin's Lymphoma

A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL

Start date: May 20, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, single-arm study to evaluate tolerability, safety and efficacy of RJMty19 in adult subjects with r/r B-NHL.

NCT ID: NCT06104553 Recruiting - Clinical trials for B-cell Non-Hodgkin's Lymphoma

A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma

Start date: November 17, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to evaluate the safety, PK and preliminary anti-tumour activity of SHR-A1912 combined with other therapies in patients with B-cell non-Hodgkin 's lymphoma.

NCT ID: NCT05771883 Not yet recruiting - Clinical trials for B-cell Non-Hodgkin's Lymphoma

A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

Start date: May 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study was to evaluate the safety and efficacy of IMM0306 in combination with lenalidomide in patients with relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma.

NCT ID: NCT05453669 Recruiting - Clinical trials for B-cell Non-Hodgkin's Lymphoma

Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL

Start date: June 15, 2022
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of CD19-CAR-DNT cells infusion in subjects with relapsed/refractory B-cell non-Hodgkin's Lymphoma

NCT ID: NCT05436223 Recruiting - Clinical trials for B-cell Non-Hodgkin's Lymphoma

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

Start date: August 9, 2021
Phase: Phase 2
Study type: Interventional

A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for R/R B-NHL. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.

NCT ID: NCT05332054 Enrolling by invitation - Lymphoma Clinical Trials

Long-Term Follow-up Study

LTFS
Start date: March 16, 2022
Phase:
Study type: Observational

This is a non-interventional, long-term safety study of allogeneic CAR-T cell therapy in patients who have participated in a prior Caribou-sponsored clinical study, in a special access program, or in another study such as an IIT. Its purpose of is to collect long-term observational data to identify and understand potential late side effects in patients who have received CAR-T cell therapies.

NCT ID: NCT05190068 Recruiting - Clinical trials for B-Cell Non-Hodgkin's Lymphoma

HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Start date: January 4, 2022
Phase: Phase 1
Study type: Interventional

A Multicenter, Open-label, Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of HMPL-760 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT ID: NCT05149391 Recruiting - Clinical trials for B Cell Non-Hodgkin's Lymphoma

A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma

Start date: July 20, 2021
Phase: Phase 1
Study type: Interventional

This is a single-center, open-label study to evaluate the safety and efficacy of C-CAR039 in relapsed and/or refractory B cell Non-Hodgkin's Lymphoma patients.

NCT ID: NCT05091541 Not yet recruiting - Clinical trials for B-cell Non-Hodgkin's Lymphoma

A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Start date: October 20, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a single-armed, open-label,multicenter Phase 1/2 study to evaluate the safety and efficacy of CT120 in subjects with relapsed/refractory B-cell non-Hodgkin's lymphoma.

NCT ID: NCT04746131 Suspended - Clinical trials for B-cell Non-Hodgkin's Lymphoma

Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

Start date: January 15, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of IMM0306-02 in patients with refractory or relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL).